Head-to-head · Cost-Efficiency Index
HealthRX vs Pallas Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
HealthRX
Shoppers who want the whole term ladder published before intake and are reading it carefully enough to spot which rung the headline came from.
Visit HealthRXPallas Health
Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Visit Pallas HealthThe verdict
HealthRX and Pallas Health tie on the Cost-Efficiency Index at 74/100, so neither wins outright on the numbers. For most shoppers we'd start with HealthRX (ranked #41, a hair above #42) — Shoppers who want the whole term ladder published before intake and are reading it carefully enough to spot which rung the headline came from. But Pallas Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs HealthRX.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | HealthRX | Pallas Health |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 74/100 |
| Semaglutide / mo | $190/mo (all doses, compounded) | $199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks |
| Tirzepatide / mo | $239/mo (all doses, compounded) | $299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks |
| Semaglutide / yr (modeled) | $2,280 | $2,388 |
| Tirzepatide / yr (modeled) | $2,868 | $3,588 |
| Coverage | All 50 states | Most states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #41 | #42 |
HealthRX
74/100Where the value is
- All 50 states, printed in the site's own header strip rather than left to the intake quiz
- Specific, checkable LegitScript certificate number (50087439) rather than just a generic badge image
- "Same price at every dose" policy avoids dose-based price creep
The tradeoffs
- The advertised $99 and $179 are twelve-month prepay rungs — $1,188 and $2,148 up front. The standing month-to-month rates are $190 and $239, roughly double and a third higher
- A second discount is stacked on the same headline: $99 semaglutide and $149 tirzepatide are also first-month intro rates on the monthly plan, so month two costs more than month one
Pallas Health
74/100Where the value is
- Both molecules are priced publicly, with the charged block stated rather than only a monthly average
- A genuinely reduced first cycle — $139 semaglutide and $179 tirzepatide for the first four weeks
- Runs a Spanish-language lander as well as the English site, which most of this field does not
The tradeoffs
- There is no monthly rung. The only cadence is a 12-week block paid up front — $597 or $897 — so the advertised 'per month' figure is arithmetic rather than a payment anyone makes
- A 12-week cycle is 4.33 charges a year, not 4, so a year costs more than four times the block
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.